Financial Report; Johnson & Johnson

Financial Report: Johnson & Johnson
3Q Revenues: $21.1 billion (+2%)
3Q Earnings: $3.6 billion (+103%)
YTD Revenues: $60.1 billion (-2%)
YTD Earnings: $13.0 billion (+17%)
Comments: Pharmaceutical sales were $11.4 billion in the quarter, up 5%, driven by DARZALEX (+44% to $1.1 billion) for the treatment of multiple myeloma, STELARA (+15% to $1.9 billion) for the treatment of a number of immune-mediated inflammatory diseases, IMBRUVICA (+12% to $1.0 billion) for use in treating certain B-cell malignancies, a type of blood or lymph node cancer, INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (+9% to $926 million) for the treatment of schizophrenia, OPSUMIT (+13% to $392 million) for the treatment of pulmonary arterial hypertension to delay disease progression, UPTRAVI (+24% to $260 million) to treat pulmonary arterial hypertension and reduce hospitalization, and ERLEADA ($206 million, up from $86 million) for the treatment of prostate cancer. This growth was partially offset by the negative impact of COVID-19 as well as biosimilar and generic competition, with declines primarily in REMICADE (-19% to $921 million) and ZYTIGA (-20% to $590 million).